Neumora Therapeutics (NASDAQ:NMRA) Insider Sells $34,464.69 in Stock

Neumora Therapeutics, Inc. (NASDAQ:NMRA) insider Paul Berns sold 9,819 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $3.51, for a total transaction of $34,464.69. Following the completion of the sale, the insider owned 7,395,185 shares in the company, valued at approximately $25,957,099.35. This trade represents a 0.13% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Neumora Therapeutics Stock Down 2.6%

NASDAQ:NMRA opened at $3.39 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.85 and a current ratio of 6.85. The company has a market capitalization of $566.43 million, a price-to-earnings ratio of -2.31 and a beta of 3.20. Neumora Therapeutics, Inc. has a one year low of $0.61 and a one year high of $3.65. The stock has a 50-day simple moving average of $2.20 and a 200 day simple moving average of $2.08.

Hedge Funds Weigh In On Neumora Therapeutics

Institutional investors have recently modified their holdings of the company. AlphaCore Capital LLC acquired a new position in Neumora Therapeutics during the 2nd quarter valued at about $248,000. Catalyst Funds Management Pty Ltd bought a new stake in shares of Neumora Therapeutics during the second quarter valued at approximately $29,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Neumora Therapeutics during the second quarter worth approximately $41,000. Savant Capital LLC bought a new position in Neumora Therapeutics in the 2nd quarter worth approximately $52,000. Finally, Y Intercept Hong Kong Ltd bought a new position in Neumora Therapeutics in the 2nd quarter worth approximately $42,000. Institutional investors own 47.65% of the company’s stock.

Key Stories Impacting Neumora Therapeutics

Here are the key news stories impacting Neumora Therapeutics this week:

• Positive Sentiment: William Blair upgraded NMRA from Market Perform to Outperform, a catalyst that helped lift shares and drew investor attention. Neumora Therapeutics (NASDAQ:NMRA) Stock Rating Upgraded by William Blair
• Positive Sentiment: Other broker research has become more bullish in recent months (Needham, RBC, Mizuho), with several firms raising price targets — a supportive backdrop for shares and longer‑term sentiment. MarketBeat: Neumora Therapeutics coverage and analyst notes
• Neutral Sentiment: Institutional ownership is meaningful (~47.7%); a mix of hedge funds/institutions recently took or adjusted positions, which can amplify moves but doesn’t signal a directional near‑term catalyst by itself. MarketBeat: Hedge funds and institutional ownership
• Neutral Sentiment: Company profile: Neumora is a clinical‑stage CNS biotech with an R&D pipeline across small molecules, biologics and gene modalities — typical risk/reward profile for a clinical-stage drug developer. MarketBeat: About Neumora Therapeutics
• Negative Sentiment: Multiple insiders sold shares on Feb. 17 (President Joshua Pinto: 5,967 shares; Paul L. Berns: 9,819; Daljit Singh Aurora: 6,165; Michael Lee Milligan: 1,436) — roughly ~23k shares disclosed — which can create downward pressure and signal near‑term caution to investors. Insider Selling: Neumora Therapeutics (NASDAQ:NMRA) President Sells 5,967 Shares of Stock

Analyst Upgrades and Downgrades

NMRA has been the topic of several research analyst reports. Guggenheim upgraded Neumora Therapeutics from a “neutral” rating to a “buy” rating and set a $14.00 price objective on the stock in a research note on Monday, October 27th. Stifel Nicolaus increased their target price on shares of Neumora Therapeutics from $2.00 to $3.00 and gave the stock a “hold” rating in a report on Monday, November 17th. William Blair raised shares of Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 17th. Royal Bank Of Canada raised shares of Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and boosted their price objective for the company from $4.00 to $7.00 in a research report on Monday, December 1st. Finally, Needham & Company LLC raised their target price on shares of Neumora Therapeutics from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Tuesday, October 28th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, Neumora Therapeutics has a consensus rating of “Hold” and a consensus price target of $8.13.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.